Cargando…
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan
OBJECTIVE: Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the se...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259303/ https://www.ncbi.nlm.nih.gov/pubmed/35342138 http://dx.doi.org/10.2169/internalmedicine.9209-21 |
_version_ | 1784741747804340224 |
---|---|
author | Fujii, Takayuki Hagihara, Masao Mitamura, Keiko Nakashima, Shiori Ohara, Shin Uchida, Tomoyuki Inoue, Morihiro Okuda, Moe Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Iwatsuki-Horimoto, Kiyoko Yamayoshi, Seiya Kawaoka, Yoshihiro |
author_facet | Fujii, Takayuki Hagihara, Masao Mitamura, Keiko Nakashima, Shiori Ohara, Shin Uchida, Tomoyuki Inoue, Morihiro Okuda, Moe Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Iwatsuki-Horimoto, Kiyoko Yamayoshi, Seiya Kawaoka, Yoshihiro |
author_sort | Fujii, Takayuki |
collection | PubMed |
description | OBJECTIVE: Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. METHODS: In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. RESULTS: In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). CONCLUSION: Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group. |
format | Online Article Text |
id | pubmed-9259303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-92593032022-07-19 Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan Fujii, Takayuki Hagihara, Masao Mitamura, Keiko Nakashima, Shiori Ohara, Shin Uchida, Tomoyuki Inoue, Morihiro Okuda, Moe Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Iwatsuki-Horimoto, Kiyoko Yamayoshi, Seiya Kawaoka, Yoshihiro Intern Med Original Article OBJECTIVE: Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. METHODS: In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. RESULTS: In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). CONCLUSION: Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group. The Japanese Society of Internal Medicine 2022-03-26 2022-06-01 /pmc/articles/PMC9259303/ /pubmed/35342138 http://dx.doi.org/10.2169/internalmedicine.9209-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Fujii, Takayuki Hagihara, Masao Mitamura, Keiko Nakashima, Shiori Ohara, Shin Uchida, Tomoyuki Inoue, Morihiro Okuda, Moe Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Iwatsuki-Horimoto, Kiyoko Yamayoshi, Seiya Kawaoka, Yoshihiro Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan |
title | Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan |
title_full | Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan |
title_fullStr | Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan |
title_full_unstemmed | Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan |
title_short | Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan |
title_sort | anti-sars cov-2 igg in covid-19 patients with hematological diseases: a single-center, retrospective study in japan |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259303/ https://www.ncbi.nlm.nih.gov/pubmed/35342138 http://dx.doi.org/10.2169/internalmedicine.9209-21 |
work_keys_str_mv | AT fujiitakayuki antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT hagiharamasao antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT mitamurakeiko antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT nakashimashiori antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT oharashin antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT uchidatomoyuki antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT inouemorihiro antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT okudamoe antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT yasuharaatsuhiro antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT murakamijurika antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT duongcalvin antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT iwatsukihorimotokiyoko antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT yamayoshiseiya antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan AT kawaokayoshihiro antisarscov2iggincovid19patientswithhematologicaldiseasesasinglecenterretrospectivestudyinjapan |